Next Workshop – Monday, June 3, 2019.
Objectives:
Describe the epidemiology of HIV in Baltimore City and Maryland State
Describe the current treatment guidelines for PrEP
Identify key populations impacted by HIV that may benefit from PrEP, including men who have sex with men, transgender persons, women planning to conceive and adolescents, and persons who inject drugs
Describe management of significant sexually transmitted infections
Demonstrate sexually history taking skills and increase comfort discussing sexuality with patients
Demonstrate and provide opportunity to practice proper techniques of extra-genital screening for sexually transmitted infections
Discuss patient education with practical approaches for patients to adhere to medication and follow up clinic visits
Identify patient support programs and novel PrEP models
Accreditation Statements:
CME: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Centers for Disease Control and Prevention and STD/HIV Prevention Training Center at Johns Hopkins. The Centers for Disease Control and Prevention is accredited by the (ACCME®) to provide medical education for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Centers for Disease Control and Prevention designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program is a designated event for pharmacists to receive 0.775 Contact Hours in pharmacy education. The Universal Activity Number is 0387-9999- 170-L01-P and 0387-9999- 170-H01-P.
Category: This activity has been designated as Knowledge-Based
Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.
Disclosure:
CDC, our planners, presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.
Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Ghanem’s discussion on STD Overview. He will be discussing extra genital screening for Gonorrhea and Chlamydia. Also with the exception of Dr. Tuddenham’s discussion on STD Overview. She will be discussing extra genital screening for Gonorrhea and Chlamydia. Also with the exception of Dr.Rompalo’s discussion on STD Overview. She will be discussing some assays may not yet be FDA cleared and are in the testing developmental phase. Also extra genital screening for gonorrhea and chlamydia. Also with the exception of Dr. Nayak’s discussion on STD Overview. She will be discussing the recently published data on the drug solithromycin. It is a potential agent for the treatment of gonorrhea, and the phase 3 data is very promising, but the drug is not currently FDA approved for the treatment of gonorrhea. I will keep my comments to data that is publicly available. This drug is important to mention because it has been published in the medical literature, and the audience will likely have questions pertaining to the data. Also Extra genital screening for gonorrhea and chlamydia.
CDC did not accept commercial support for this continuing education activity.
Registration
Registration is closed.
Learn More about PrEP. Join us on Facebook